pre-IPO PHARMA

COMPANY OVERVIEW

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. The company’s proprietary technology platform, XTreo™, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration.


LOCATION

  • Watertown, MA, USA

  • THERAPEUTIC AREAS

  • Inflammatory DIsease

  • WEBSITE

    https://lyratherapeutics.com


    CAREER WEBSITE

    https://lyratherapeutics.com/careers/job-opportunities/


    SOCIAL MEDIA


    INVESTORS

    arrowmark-partners intersouth-partners north-bridge-venture-partners perceptive-advisors polaris-partners ra-capital soleus-capital


    PRESS RELEASES


    Feb 17, 2022

    Lyra Therapeutics Appoints Harlan W. Waksal, MD, as Executive Chairman


    Jan 24, 2022

    Lyra Therapeutics Announces Initiation of LYR-210 Pivotal Phase 3 ENLIGHTEN Program in Surgically Naïve Chronic Rhinosinusitis Patients


    Nov 9, 2021

    Lyra Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update


    Oct 4, 2021

    Lyra Therapeutics Presents New Positive Phase 2 LANTERN 6-Month Follow-Up and LYR-210 Pharmacokinetic Data, and LANTERN Manuscript Wins Award at the 67th Annual Meeting of the American Rhinologic Society


    Feb 1, 2021

    ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Lyra Therapeutics, Inc. and Encourages Investors with Losses to Contact the Firm


    For More Press Releases


    Google Analytics Alternative